Kutsuki H. β2-Microglobulin-selective direct hemoperfusion column for the treatment of dialysis-related amyloidosis.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS 2005;
1753:141-5. [PMID:
16168723 DOI:
10.1016/j.bbapap.2005.08.007]
[Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/16/2005] [Revised: 08/01/2005] [Accepted: 08/01/2005] [Indexed: 11/17/2022]
Abstract
Lixelle is a direct hemoperfusion-type adsorption column that was developed to selectively eliminate beta2-microglobulin (beta2-m) from the circulating blood of patients with dialysis-related amyloidosis (DRA). The adsorbent in Lixelle comprises porous cellulose beads to which hydrophobic hexadecyl alkyl chain is covalently bound. One milliliter of wet Lixelle beads eliminates more than 1 mg of beta2-m in vitro. In hemodialysis patients who were treated with Lixelle, Lixelle improved joint pain, nocturnal awakening, pinch strength, motor terminal latency, and their activity of daily living. The adsorbent adsorbs beta2-m selectively but not specifically, as well as inflammatory cytokines such as interleukin-1beta and IL-6 which are considered to be involved in the development of DRA. Lixelle treatments reduce the circulating levels of beta2-m and inflammatory cytokines, thereby improving the symptoms of patients with DRA.
Collapse